A Retrospective Real-world Claims Analysis Showed Most Schizophrenia Patients Returned for Treatment
After treatment with INVEGA SUSTENNA® for at least 4 months, the majority of adult schizophrenia patients who were transitioned to INVEGA TRINZA® per label* returned for treatment
Based on a retrospective cohort analysis of pharmacy and medical claims data, of adult patients with schizophrenia (n=1603), from the Symphony Health Solutions (SHS) database from May 2014 to September 2016. First data on patient claims for INVEGA TRINZA® were from July 2015.
Claims databases such as SHS are subject to billing inaccuracies and missing data
Data are real-world usage patterns only; there are no associated clinical/economic outcomes
Findings are based on medication dispensed date, not administration of medication
Patient Claims Data
SHS, a robust open-source database, captures prescription transactions for roughly 75% of the US population annually (approximately 260 million patients). The database does not capture services received outside of the SHS network.6